📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr; PAT Up 14% to ₹445 Cr
Godrej Agrovet reported a robust FY26 with consolidated revenue growing 9.1% to ₹10,233 crore and PAT increasing 13.9% to ₹440 crore (excluding non-recurring items). The performance was driven by strong volume growth in Animal Nutrition (12%) and a landmark year for the Oil Palm business, which saw a 68% jump in segment results. While Crop Care and Dairy faced headwinds from weather and high procurement costs, Astec LifeSciences achieved an EBITDA turnaround. Notably, the company significantly optimized its working capital cycle to 25 days, leading to an improved ROCE of 20%.
Key Highlights
Consolidated revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crore in FY26.
Oil Palm segment result grew by 67.9% YoY, driven by record oil extraction ratios and supportive pricing.
Animal Nutrition volumes grew 12% YoY, with cattle feed specifically rising by 18%.
Net Working Capital cycle significantly improved from 39 days to 25 days, boosting ROCE to 20%.
Astec LifeSciences achieved EBITDA break-even in FY26 with a sharp reduction in losses.
👀 What to Watch
Investors should monitor the sustained recovery in Astec LifeSciences and the margin stability in the Dairy segment. The company's focus on capital efficiency and branded products in the poultry business makes it a strong long-term play in the agri-conglomerate space.
Godrej Agrovet FY26 Revenue Crosses ₹10,000 Cr; PBT Grows 17% YoY to ₹569 Cr
Godrej Agrovet delivered a strong FY26 performance with consolidated revenue growing 9% YoY to ₹10,233 crore, crossing the ₹10,000 crore milestone. Profit before tax (excluding exceptional items) rose 17% to ₹569 crore, supported by a 68% growth in the Oil Palm segment and a turnaround in Astec LifeSciences which reached EBITDA break-even. While the Animal Nutrition business saw 12% volume growth, the Dairy and Crop Care segments faced headwinds from unseasonal rains and high procurement costs. The company also reported improved working capital management and a tangible increase in ROCE.
Key Highlights
Consolidated FY26 revenue reached ₹10,233 crore, a 9% increase over FY25.
FY26 PBT (excluding non-recurring items) grew 17% YoY to ₹569 crore.
Oil Palm segment results surged by ~68% YoY driven by peak oil recovery and volume growth.
Animal Nutrition volumes grew 12% in FY26, with cattle feed volumes specifically rising 18%.
Astec LifeSciences achieved EBITDA break-even in FY26, marking a significant turnaround from previous losses.
👀 What to Watch
Investors should note the strong recovery in Astec LifeSciences and the robust growth in the Oil Palm and Animal Nutrition segments as key value drivers. While Dairy and Crop Care remain under pressure, the shift toward branded products and improved capital efficiency supports a positive long-term outlook.
Godrej Agrovet FY26 PAT Up 10.4% to ₹445 Cr; ₹11 Dividend Declared
Godrej Agrovet reported a steady financial performance for FY26, with consolidated revenue from operations growing 9% to ₹10,232.68 crore. Full-year consolidated net profit increased by 10.4% to ₹445.18 crore, supported by a strong Q4 performance where profit jumped to ₹102.28 crore from ₹66.10 crore YoY. The Board has recommended a final dividend of ₹11 per share (110% of face value). The company also announced the allotment of 30,973 shares under its ESOP scheme.
Key Highlights
Consolidated Revenue for FY26 rose to ₹10,232.68 crore, up from ₹9,382.77 crore in FY25.
Full-year Consolidated Profit After Tax (PAT) grew 10.4% YoY to ₹445.18 crore.
Recommended a final dividend of ₹11.00 per equity share (110%) for FY 2025-26.
Q4 FY26 consolidated PAT stood at ₹102.28 crore, a significant jump from ₹66.10 crore in the same quarter last year.
Paid-up equity share capital increased to ₹192.36 crore following the allotment of 30,973 ESOP shares.
👀 What to Watch
Investors may find the steady earnings growth and healthy dividend yield attractive; focus should remain on the company's ability to maintain margins amidst fluctuating agri-commodity prices.
Godrej Agrovet FY26 PAT Rises 10% to ₹445 Cr; Recommends ₹11 Dividend
Godrej Agrovet reported a steady financial performance for FY 2025-26, with consolidated revenue growing 9.1% YoY to ₹10,232.68 crore. Net profit for the year increased by 10.4% to ₹445.18 crore, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹11 per share (110% of face value). Additionally, the company managed its employee stock options by allotting 30,973 shares and granting 50,507 new options to eligible employees.
Key Highlights
Consolidated Revenue from Operations grew 9.1% YoY to ₹10,232.68 crore in FY26.
Consolidated Net Profit (PAT) increased to ₹445.18 crore from ₹403.37 crore in the previous fiscal.
Recommended a final dividend of ₹11.00 per equity share for the financial year 2025-26.
Basic Earnings Per Share (EPS) rose to ₹24.58 compared to ₹22.35 in FY25.
Allotted 30,973 equity shares and granted 50,507 new stock options under the ESGS 2018 scheme.
👀 What to Watch
The steady earnings growth and healthy dividend payout make this a positive result for long-term investors. Shareholders should monitor the upcoming AGM on August 5, 2026, for further management commentary on growth outlook.
Godrej Agrovet FY26 Net Profit Rises 10% to ₹445 Cr; Recommends ₹11 Dividend
Godrej Agrovet reported a steady performance for FY 2025-26, with consolidated revenue crossing the ₹10,000 crore milestone, reaching ₹10,232.68 crore. Net profit for the full year grew by 10.4% YoY to ₹445.18 crore. The Board has recommended a substantial final dividend of ₹11 per share (110% of face value). Additionally, the company processed an ESOP allotment of 30,973 shares and granted 50,507 new stock options to employees.
Key Highlights
Consolidated Revenue from Operations grew 9% YoY to ₹10,232.68 crore for FY26.
Consolidated Net Profit for the full year increased to ₹445.18 crore from ₹403.37 crore in FY25.
Recommended a final dividend of ₹11.00 per equity share of face value ₹10 each.
Q4 FY26 consolidated profit jumped 54.7% YoY to ₹102.28 crore compared to ₹66.10 crore.
Allotted 30,973 equity shares under ESGS 2018, increasing paid-up capital to ₹192.36 crore.
👀 What to Watch
The strong Q4 performance and consistent annual growth, coupled with a healthy dividend payout, make this a positive update for long-term investors. Monitor the upcoming AGM on August 5, 2026, for further management commentary on growth outlook.
Godrej Agrovet FY26 Net Profit Rises 10% to ₹445 Cr; Recommends ₹11 Dividend
Godrej Agrovet reported a steady performance for FY26, with consolidated net profit growing 10.4% year-on-year to ₹445.18 crore. Annual revenue from operations crossed the ₹10,000 crore mark, reaching ₹10,232.68 crore, up from ₹9,382.77 crore in FY25. The Board has recommended a substantial final dividend of 110% or ₹11 per share. Additionally, the company is active on employee incentives, granting 50,507 new stock options while allotting 30,973 shares under existing schemes.
Key Highlights
Consolidated FY26 revenue increased 9% YoY to ₹10,232.68 crore.
Consolidated net profit for the full year rose to ₹445.18 crore from ₹403.37 crore in FY25.
Recommended a final dividend of ₹11.00 per equity share for the financial year 2025-26.
Q4 FY26 consolidated profit surged to ₹102.28 crore compared to ₹66.10 crore in the same quarter last year.
Granted 50,507 new stock options to employees at an exercise price of ₹10 per share.
👀 What to Watch
The consistent growth in both top-line and bottom-line figures, coupled with a healthy dividend payout, makes this a positive result for long-term holders. Investors should note the record date of July 29, 2026, to be eligible for the ₹11 dividend.
Godrej Agrovet Recommends Rs 11 Dividend; FY26 Consolidated Profit Rises 10% to Rs 445 Cr
Godrej Agrovet reported a steady performance for FY 2025-26, with consolidated revenue growing 9.1% to Rs 10,232.68 crore. Consolidated net profit for the year increased by 10.4% to Rs 445.18 crore compared to the previous year. Reflecting this growth, the board has recommended a final dividend of Rs 11.00 per share (110% of face value). The company has fixed July 29, 2026, as the record date for dividend eligibility, with payment expected by August 10, 2026.
Key Highlights
Consolidated revenue for FY26 reached Rs 10,232.68 crore, up from Rs 9,382.77 crore in FY25.
Consolidated net profit grew to Rs 445.18 crore for the full year, compared to Rs 403.37 crore in FY25.
Recommended a final dividend of Rs 11.00 per equity share of face value Rs 10 each.
Record date for dividend entitlement is July 29, 2026, with the AGM scheduled for August 5, 2026.
Company allotted 30,973 equity shares under its Employee Stock Grant Scheme (ESGS 2018).
👀 What to Watch
Investors should consider the steady earnings growth and healthy dividend payout as positive indicators of financial health. Ensure holdings are in place before the July 29 record date to qualify for the Rs 11 dividend.
Godrej Agrovet FY26 PAT Rises 10.4% to ₹445 Cr; Recommends ₹11 Dividend
Godrej Agrovet reported a steady performance for FY26, with consolidated revenue crossing the ₹10,000 crore mark to reach ₹10,232.68 crore. Consolidated Net Profit for the full year grew by 10.4% to ₹445.18 crore, while the Q4 performance showed a sharp jump in profit to ₹102.28 crore compared to ₹66.10 crore in the previous year's quarter. The board has recommended a final dividend of ₹11 per share (110% of face value). The company also announced the allotment of 30,973 equity shares under its employee stock grant scheme.
Key Highlights
Consolidated Revenue for FY26 grew 9% YoY to ₹10,232.68 crore from ₹9,382.77 crore.
Consolidated Net Profit (PAT) increased to ₹445.18 crore for FY26, up from ₹403.37 crore in FY25.
Board recommended a final dividend of ₹11.00 per equity share for the financial year 2025-26.
Q4FY26 Consolidated PAT surged to ₹102.28 crore, representing a significant growth over ₹66.10 crore in Q4FY25.
Total Consolidated Assets increased to ₹6,170.19 crore as of March 31, 2026, compared to ₹5,515.99 crore in the previous year.
👀 What to Watch
Investors should take note of the consistent top-line growth and the healthy dividend yield; the strong Q4 performance suggests improving operational efficiency which may support the stock price.
Godrej Agrovet FY26 Revenue Crosses ₹10,000 Cr; PAT Up 10%, ₹11 Dividend Declared
Godrej Agrovet reported a steady performance for FY26, with consolidated revenue crossing the ₹10,000 crore milestone, reaching ₹10,232.68 crore. Net profit attributable to owners grew by 10% YoY to ₹472.78 crore, up from ₹429.72 crore in the previous fiscal. The board has recommended a substantial final dividend of ₹11 per share (110% of face value). The company's balance sheet remains healthy with total assets expanding to ₹6,170.19 crore as of March 31, 2026.
Key Highlights
Consolidated Revenue from Operations grew 9.06% YoY to ₹10,232.68 crore in FY26.
Net Profit attributable to owners rose 10.02% YoY to ₹472.78 crore.
Recommended a final dividend of ₹11.00 per equity share for the financial year 2025-26.
Consolidated Basic EPS increased to ₹24.58 from ₹22.35 in the previous fiscal year.
Total Consolidated Assets increased by approximately 11.8% to ₹6,170.19 crore.
👀 What to Watch
Investors should find the steady earnings growth and the ₹11 dividend payout attractive for long-term holding. The crossing of the ₹10,000 crore revenue mark signals strong scale in the agri-business sector.
Godrej Agrovet Shareholders Approve Re-appointment of Dr. Ashok Gulati with 99.99% Majority
Godrej Agrovet Limited has successfully passed a special resolution via postal ballot for the re-appointment of Dr. Ashok Gulati as a Non-Executive Independent Director. The resolution received overwhelming support with 99.9862% of votes cast in favour. A total of 14.51 crore votes were polled, representing approximately 75.45% of the company's total equity shares. Dr. Gulati's second term will run from May 7, 2026, through May 10, 2029, ensuring continuity in the company's independent board oversight.
Key Highlights
Special resolution for re-appointment of Dr. Ashok Gulati passed with 99.9862% votes in favour.
Total valid votes polled were 14,51,04,181, accounting for 75.45% of the total 19.23 crore outstanding shares.
Promoter and Promoter Group cast 13.02 crore votes, all 100% in favour of the resolution.
Public institutional holders showed strong support with 99.87% of their 1.47 crore votes in favour.
The new term for the Independent Director is effective from May 7, 2026, to May 10, 2029.
👀 What to Watch
Investors should take confidence in the high level of shareholder consensus and the continuity of experienced independent leadership on the board. No immediate portfolio action is required as this is a positive governance-related update.
Godrej Agrovet Appoints Burjis Godrej as Chairman-Designate; Nadir Godrej to Retire in Aug 2026
Godrej Agrovet has announced a structured leadership succession plan where Mr. Nadir Godrej will retire as Chairman on August 13, 2026. Mr. Burjis Godrej, currently an Executive Director, has been appointed as Chairman-Designate effective April 13, 2026, and will formally assume the Chairperson role on August 14, 2026. Mr. Burjis Godrej brings significant operational experience, having served as MD of Astec LifeSciences (2025-2026) and COO of Crop Care (2023-2024). This long-term transition plan is designed to ensure stability and continuity in the company's strategic vision.
Key Highlights
Mr. Nadir Godrej to retire as Chairman and Non-Executive Director effective August 13, 2026.
Mr. Burjis Godrej appointed as Chairman-Designate effective April 13, 2026, and Chairman from August 14, 2026.
Mr. Nadir Godrej will be appointed as Chairman Emeritus starting August 14, 2026.
Burjis Godrej holds an MBA from Harvard and previously led Astec LifeSciences as MD from 2025 to 2026.
👀 What to Watch
Investors should view this as a positive sign of transparent succession planning which reduces governance risk. No immediate portfolio changes are recommended as the transition period spans over a year.
Godrej Agrovet Announces Leadership Succession: Burjis Godrej to Succeed Nadir Godrej as Chairman
Godrej Agrovet has announced a planned leadership transition where Mr. Nadir Godrej will retire as Chairman on August 13, 2026. His son, Mr. Burjis N. Godrej, currently an Executive Director, has been appointed as Chairman-Designate immediately and will take over as Chairperson on August 14, 2026. Mr. Nadir Godrej will continue his association with the company as Chairman Emeritus. This move ensures a smooth succession within the promoter family, leveraging Burjis Godrej's experience as former MD of Astec LifeSciences.
Key Highlights
Mr. Nadir Godrej to retire as Chairman and Non-Executive Director effective August 13, 2026.
Mr. Burjis N. Godrej appointed as Chairman-Designate effective April 13, 2026, and Chairperson from August 14, 2026.
Mr. Nadir Godrej will transition to the role of Chairman Emeritus starting August 14, 2026.
Successor Burjis Godrej previously served as MD of Astec LifeSciences (2025-2026) and COO of Crop Care (2023-2024).
👀 What to Watch
Maintain current positions as this is a planned succession that ensures continuity. Monitor the transition process leading up to August 2026.
Nadir Godrej to Retire as Godrej Agrovet Chairman; Burjis Godrej Named Successor
Godrej Agrovet has announced a planned leadership transition with Mr. Nadir Godrej set to retire as Chairman on August 13, 2026. He will be succeeded by Mr. Burjis N. Godrej, who has been appointed Chairman-Designate effective April 13, 2026, and will formally take over as Chairperson on August 14, 2026. Mr. Burjis Godrej, an MBA from Harvard, brings significant experience having served as MD of Astec LifeSciences and COO of the company's Crop Care division. To ensure continuity, Mr. Nadir Godrej will remain associated with the company as Chairman Emeritus.
Key Highlights
Mr. Nadir Godrej to retire as Chairman and Non-Executive Director on August 13, 2026.
Mr. Burjis N. Godrej appointed as Chairperson effective August 14, 2026, and Chairman-Designate immediately.
Successor Burjis Godrej previously served as MD of Astec LifeSciences (2025-2026) and COO of Crop Care (2023-2024).
Mr. Nadir Godrej will transition to the role of Chairman Emeritus starting August 14, 2026.
The transition follows a clear succession plan within the promoter family and existing executive leadership.
👀 What to Watch
Investors should view this as a positive sign of structured succession planning which ensures business continuity. No immediate portfolio changes are recommended as the transition is well-telegraphed and involves an experienced internal candidate.
Nadir Godrej to Retire; Burjis N. Godrej Appointed Chairman Effective August 14, 2026
Godrej Agrovet has announced a major leadership transition as Mr. Nadir Godrej will retire as Chairman and Non-Executive Director on August 13, 2026. He will be succeeded by his son, Mr. Burjis N. Godrej, who has been appointed as Chairperson effective August 14, 2026, and will serve as Chairman-Designate starting April 13, 2026. Mr. Burjis Godrej brings significant experience, having previously served as the MD of Astec LifeSciences and COO of Godrej Agrovet's Crop Care business. This planned succession is intended to ensure leadership continuity within the promoter family.
Key Highlights
Mr. Nadir Godrej to retire as Chairman and Non-Executive Director effective close of business on August 13, 2026.
Mr. Burjis N. Godrej appointed as Chairperson effective August 14, 2026, and Chairman-Designate from April 13, 2026.
Mr. Nadir Godrej will take on the role of 'Chairman Emeritus' starting August 14, 2026.
Successor Burjis Godrej holds an MBA from Harvard and previously served as MD of Astec LifeSciences (2025-2026).
The transition period spans four months to ensure a smooth handover of responsibilities.
👀 What to Watch
Investors should view this as a planned and transparent succession move that maintains promoter-level continuity. Monitor the company's strategic focus under the new leadership, particularly in capital allocation and new business models.
Godrej Agrovet Appoints Vivek Shah as Head of Sales Development Effective April 2026
Godrej Agrovet has appointed Mr. Vivek Shah as the Head of Sales Development, effective April 10, 2026. Mr. Shah joins with nearly 20 years of experience from FMCG leaders Marico and Britannia, where he managed business portfolios worth up to ₹2,000 crore. His track record includes expanding rural distribution by 40% and leading large-scale digital sales transformations. This strategic hire is aimed at strengthening the company's go-to-market capabilities and driving commercial excellence across its diverse business verticals.
Key Highlights
Vivek Shah appointed as Head - Sales Development starting April 10, 2026
Brings nearly 20 years of experience in FMCG sales and business turnarounds from Marico and Britannia
Previously managed business units with turnovers up to ₹2,000 crore and led teams of 200+ members
Successfully expanded rural distribution by 40% and led digital GTM transformations in previous roles
Focus at Godrej Agrovet will be on strengthening GTM capabilities and driving commercial excellence
👀 What to Watch
Investors should view this as a positive move to professionalize and scale the company's distribution network. Monitor for improvements in sales efficiency and market penetration in the quarters following his start date.
Godrej Agrovet Re-appoints Dr. Ashok Gulati as Independent Director for Second Term until 2029
Godrej Agrovet has approved the re-appointment of Dr. Ashok Gulati as a Non-Executive Independent Director for a second term effective from May 7, 2026, to May 10, 2029. Dr. Gulati is a highly distinguished agricultural economist and a Padma Shri awardee, bringing significant domain expertise to the board. His background includes serving as Chairman of the Commission for Agricultural Costs and Prices (CACP) and holding board positions at the RBI and NABARD. The appointment is subject to shareholder approval via a postal ballot process.
Key Highlights
Re-appointed for a second term of 3 years commencing May 7, 2026, and ending May 10, 2029.
Dr. Gulati is a Padma Shri recipient (2015) and former Chairman of the Commission for Agricultural Costs and Prices (2011-14).
Extensive institutional experience including past roles on the boards of RBI, NABARD, NCDEX, and Kotak Mahindra Bank.
The Board has approved a Postal Ballot to seek shareholder approval for this re-appointment.
👀 What to Watch
Investors should view this as a positive development for long-term governance and strategic oversight, as Dr. Gulati's expertise aligns perfectly with the company's core agricultural business. No immediate portfolio changes are necessary.
Godrej Agrovet to Sell Leasehold Land Rights in Gujarat for Rs. 35 Crore
Godrej Agrovet Limited has entered into an agreement to transfer and sell its leasehold rights for land located in the GIDC Sachin Industrial Estate, Gujarat. The transaction involves a total consideration of Rs. 35 Crore for Plot Nos. 247/1 and 247/2. This move appears to be an asset monetization strategy for non-core or underutilized land assets. The cash inflow is expected to strengthen the company's balance sheet or provide capital for core business operations.
Key Highlights
Agreement signed on March 18, 2026, for the transfer of leasehold land rights.
Total consideration for the transaction is fixed at Rs. 35 Crore.
Property located at GIDC Sachin Industrial Estate, Surat, Gujarat, covering multiple survey numbers.
The sale is disclosed as a material event under SEBI Listing Obligations and Disclosure Requirements.
👀 What to Watch
Investors should view this as a positive step toward capital efficiency through the monetization of non-core assets. Monitor the company's next quarterly report to see how these proceeds are utilized for debt reduction or growth capital.
Godrej Agrovet Receives 'IND AA' Rating for ₹7,500 Million Bank Facilities; Outlook Stable
India Ratings & Research has assigned a long-term rating of 'IND AA' with a stable outlook to Godrej Agrovet's bank loan facilities totaling ₹7,500 million. Additionally, the company secured a short-term rating of 'IND A1+' for facilities worth ₹500 million. These high-grade ratings indicate a very low risk of default and strong financial stability. The total rated bank facilities under this intimation amount to ₹8,000 million.
Key Highlights
Long-term rating of 'IND AA' assigned to ₹7,500 million bank loan facilities
Short-term rating of 'IND A1+' assigned to ₹500 million bank loan facilities
Outlook on the long-term rating is categorized as 'Stable'
Ratings assigned by India Ratings & Research as of March 17, 2026
👀 What to Watch
The high credit ratings confirm Godrej Agrovet's strong credit profile and low financial risk; investors should maintain their positions as the company demonstrates robust debt-servicing capabilities.
Godrej Agrovet Q3 FY26: 11% Revenue Growth and 23% PBT Increase
Godrej Agrovet reported a strong Q3 FY26 with consolidated revenue growing 11% YoY and PBT (before exceptional items) rising 23%. The performance was bolstered by a 27% revenue jump in the Vegetable Oil business and a 12% volume growth in Animal Feed. Astec LifeSciences showed a sharp recovery with 33% revenue growth and a return to positive EBITDA of INR 5 crores. Management indicated a strategic portfolio review is underway to prioritize high-growth segments, with updates expected by April 2026.
Key Highlights
Consolidated revenue grew 11% YoY in Q3 FY26, while 9M FY26 PBT rose 17% to INR 482 crores.
Vegetable Oil segment revenue grew 27% YoY with a record oil extraction ratio (OER) of 21%.
Animal Feed volumes increased 12% YoY, led by a significant 21% growth in cattle feed.
Astec LifeSciences turned EBITDA positive at INR 5 crores compared to a loss in the previous year.
Branded salience in the Foods business reached 81%, driving a 51% YoY growth in segment EBITDA to INR 17 crores.
👀 What to Watch
Investors should maintain a positive outlook given the operational efficiencies and the turnaround in Astec LifeSciences. Key focus should remain on the upcoming strategic portfolio review in April 2026 which may unlock further value.
Godrej Agrovet Launches 'TAKAI' Insecticide for Rice Crops to Combat 40% Yield Loss
Godrej Agrovet has launched 'TAKAI,' a new insecticide for rice crops powered by Cyclapryn™ technology from ISK Japan. The product specifically targets Stem Borer and Leaf Folder pests, which are responsible for yield losses of up to 40% and 30% respectively in Indian rice farming. With India producing 150.18 million tonnes of rice annually but maintaining low yields of 2.9 tonnes/hectare, this product addresses a significant productivity gap. The company is also pursuing label approvals to expand the product's use to six additional crops, including Maize, Soybean, and Sugarcane.
Key Highlights
Launched 'TAKAI' insecticide targeting pests that cause 30-40% yield loss in rice crops.
Powered by advanced Cyclapryn™ technology through a strategic partnership with ISK Japan.
Addresses a massive domestic market where India produces 150.18 million tonnes of rice annually.
Expansion plans in progress for label approvals in Maize, Chilli, Cabbage, Soybean, Chickpea, and Sugarcane.
Recommended application of 160 ml dose provides long-lasting protection during critical growth stages.
👀 What to Watch
Investors should view this as a positive development for the Crop Protection segment, as it strengthens the portfolio with high-tech, high-impact solutions. Monitor the upcoming label approvals for other crops as they will be key drivers for volume growth in the medium term.
